The P-II study evaluates cemdisiran vs PBO in a ratio (2:1) in 31 patients aged ≥18 & ≤ 65yrs. with IgAN
The results showed a 37% reduction in 24hr. UPCR @32wks. & showed an equivalent reduction in 24-hour urine total protein (36%), ≥50 percent reduction in 24-hour UPCR (32% vs 13%). The results were consistent with 24hr. urine data with the initial onset of treatment effect as early as 8wk. & remains stable over time, patients also achieved a 46% PBO-adjusted reduction from baseline in spot UPCR @32wks.
The therapy was well tolerated with no AEs & no drug-related sev. AEs along with consistent proteinuria reduction were observed with 2EPs. The therapy showed favorable effects on different measures of proteinuria
Ref: Alnylam | Image: Alnylam
